Fulgent Genetics, Inc. (FLGT) financial statements (2021 and earlier)

Company profile

Business Address 4978 SANTA ANITA AVENUE, SUITE 205
TEMPLE CITY, CA 91780
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2832272931334
Cash and cash equivalents122195784
Short-term investments161218242424 
Receivables7565665
Other current assets2222323
Other undisclosed current assets      27
Total current assets:37393536404138
Noncurrent Assets
Operating lease, right-of-use asset33  
Property, plant and equipment6666677
Long-term investments and receivables43121310862
Long-term investments43121310862
Other noncurrent assets0000000
Deferred tax assets, net 11
Other undisclosed noncurrent assets  33  7
Total noncurrent assets:52222219141417
TOTAL ASSETS:89615656545556
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3433323
Accounts payable2211112
Accrued liabilities1211111
Taxes payable00     
Deferred revenue0   
Debt00     
Other undisclosed current liabilities  00   
Total current liabilities:4433323
Noncurrent Liabilities
Long-term debt and lease obligation22     
Operating lease, liability22  
Liabilities, other than long-term debt    000
Other liabilities    000
Other undisclosed noncurrent liabilities  22   
Total noncurrent liabilities:2222000
Total liabilities:6756323
Stockholders' equity
Stockholders' equity attributable to parent83555150515353
Common stock0000000
Additional paid in capital146117116115114114113
Accumulated other comprehensive income (loss)0000(0)(0)(0)
Accumulated deficit(63)(63)(65)(65)(63)(61)(60)
Total stockholders' equity:83555150515353
TOTAL LIABILITIES AND EQUITY:89615656545556

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues81085665
Cost of revenue(4)(4)(4)(3)(3)(3)(3)
Gross profit:5652333
Operating expenses(5)(5)(5)(4)(4)(4)(4)
Operating income (loss):(0)20(2)(1)(1)(1)
Other undisclosed income from continuing operations before equity method investments, income taxes0000000
Income (loss) from continuing operations before equity method investments, income taxes:(0)20(2)(1)(1)(1)
Loss from equity method investments(0)(0)(0)(0)(0)(0)(0)
Income (loss) from continuing operations before income taxes:(0)20(2)(1)(1)(1)
Income tax expense (benefit)0(0)(0)(0)(1)00
Net income (loss) available to common stockholders, diluted:(0)10(2)(2)(1)(1)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(0)10(2)(2)(1)(1)
Other comprehensive income (loss) (0)000  
Other undisclosed comprehensive income0      
Comprehensive income (loss):(0)10(2)(2)(1)(1)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)    00
Comprehensive income (loss), net of tax, attributable to parent:(0)10(2)(2)(1)(1)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: